Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.

Slides:

Advertisements

Similar presentations

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Home Visits during Pregnancy Enhance Male Partner HIV Testing: A Randomized Clinical Trial.

Advertisements

The effect of changes in Kenya HIV guidelines on proportion of patients on ART and patient characteristics at initiation in Lumumba Health Centre, Western.

PMTCT FAILURE: THE ROLE OF MATERNAL AND FACILITY –RELATED FACTORS ICASA Presentation 8 th to 12 th Dec 2013 Onono Maricianah 1, Elizabeth A. Bukusi 1,

Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.

Retention across the continuum of care in a cohort of HIV infected children in rural India G. Alvarez-Uria RDT Hospital, Department of Infectious Diseases,

PMTCT program in Arua Uganda Lessons learned after 5 years of experience Experts Roundtable June 2008 Geneva.

Prevalence of and Progression to Abnormal Non-Invasive Markers of Liver Disease (APRI and FIB-4) among US HIV-infected Youth Kapogiannis B, Leister E,

Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

THE CORE STUDY COMPARING TWO STRATEGIES FOR ENROLLING HIV-INFECTED PREGNANT WOMEN FROM ANTENATAL CARE TO CARE AND TREATMENT SERVICES IN CAMEROON: CONTINUUM.

Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,

PMTCT HIV AND SYPHILIS IMPLEMENTATION Dr John Kinuthia, MBChB, MMED, MPH Consultant Obstetrician & Gynaecologist Honorary Lecturer, Department of Obstetrics.

Peripartum Valacyclovir Improves Markers of HIV-1 Disease Progression in Women Co-Infected with HSV-2: A Randomized Trial Alison C. Roxby, MD, MSc. July.

J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,

Validating five questions of antiretroviral non-adherence in a decentralized public-sector antiretroviral treatment program in rural South Africa Krisda.

Reproductive Health Needs of Men and Women Enrolled in HIV Care and Treatment Services Elaine Abrams August 12, 2008 Track 1.0 Meeting.

Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.

Peter F. Rebeiro, PhD, MHS On behalf of: Carina Cesar, Bryan E. Shepherd, Raquel B. De Boni, Claudia Cortés, Fernanda Rodriguez, Pablo Belaunzarán-Zamudio,

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

Sustained Treatment as Prevention: Unprotected sex and increases in virological suppression after HAART initiation among participants in HPTN K.H.

The Immunologic Efficacy of Antiretroviral Therapy among HIV-infected Patients in North America and Africa Elvin Geng* 1, Eric Vittinghoff 1, Jean Nachega.

Transition Program of HIV-infected adolescents to Adult HIV care in Buenos Aires, Argentina S. Arazi Caillaud 1, D. Mecikovsky 1, A.Bordato.

Impact of HSV-2 suppressive therapy with daily acyclovir on HIV-1 disease progression: a randomized placebo- controlled trial in Rakai, Uganda Steven J.

Effectiveness of Contraception for HIV-Infected Women using Antiretroviral Therapy Maria Pyra a,b, Renee Heffron a,b, Nelly R. Mugo b,d,e,

Washington D.C., USA, July 2012www.aids2012.org Equal behaviors, unequal risks: The role of partner transmission potential in racial HIV disparities.

Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,

Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.

The Positive Predictive Value of World Health Organization (WHO) Immunologic Criteria for Treatment Failure in a Public Health Antiretroviral Delivery.

Primary HIV-1 Infection Pathogenesis, Diagnosis, and Treatment Summary of Evidence Martin Markowitz M.D. Clinical Director and Staff Investigator Aaron.

The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.

Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2010* * Numbers are based on reports received rather than children seen to.

HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.

The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children Heidi M.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.

Supported by: NIAID/NHLBI R24 AI067039, NIAID R21 AI Viremia copy-years: A measure of cumulative HIV burden among patients initiating antiretroviral.

Provider initiated testing in Kenya Ruth Nduati Associate Prof Paediatrics University of Nairobi.

12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.

Effect of High-Dose HSV-2 Suppressive Therapy on Plasma HIV-1 RNA levels: a randomized, cross over trial 6 th IAS conference, Rome, Italy th July,

Alison Drake International AIDS Society Conference July 18, 2011 Valacyclovir suppression reduces breast milk and plasma HIV-1 RNA postpartum: results.

Scaling up access to HIV treatment: comparing outcomes among children receiving treatment at mobile and hospital-based HIV clinics in rural Zambia Janneke.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

HIV Testing in Acute Care Settings Rich Rothman, MD, PhD, FACEP CDC, DHHS, OraSure Technologies, Abbott  Historical.

Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.

Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.

Estimating the population impact of homelessness on HIV viral suppression among people who use drugs Brandon DL Marshall, 1 Beth Elson, 1 Sabina Dobrer,

Effect of ART on malaria parasitaemia and clinical episodes in adults in rural Uganda: A population-based cohort study Billy N. Mayanja 1, Kathy Baisley.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Date of download: 6/3/2016 From: U.S. Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads, and CD4 T-Lymphocyte Cell Counts Among HIV-Infected.

Illness during pregnancy is associated with in utero human immunodeficiency virus type-1 transmission Carey Farquhar, MD, MPH University of Washington/University.

A MISSED OPPORTUNITY FOR PMTCT SERVICES: SUCCESSFUL ANTENATAL HIV SCREENING AND POOR LINKAGES TO HIV CARE AND TREATMENT Changala Mable, Sikazwe Izukanji,

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

1 Predictors of virological failure in a Cambodian setting Sokkab An, M.D Sihanouk Hospital Center of HOPE (SHCH), Phnom Penh, Cambodia.

Emory University School of Medicine Department of Medicine

Pregnancy and living with HIV

Earlier treatment and lower mortality in infants Initiating ART at

Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.

Title Factors associated with viral suppression among adolescents living with HIV in Cambodia “No conflicts of interest to declare”

VESTED Quiz Game

Conclusions & Implications

VESTED Quiz Game

Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”.

Validating Definitions of Antiretroviral Treatment Failure in Malawi

Utilizing research as an opportunity to strengthen

Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2

at Anonymous Clinic, The Thai Red Cross AIDS Research Centre

Poster WP41; Contact: David A. Katz,

Volume 5, Issue 1, Pages e35-e44 (January 2018)

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

Presentation transcript:

Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101 Alison L. Drake 1, John Kinuthia 7, Daniel Matemo 7, R. Scott McClelland 1,2,3, Barbra Richardson 4, Julie Overbaugh 6, Grace John-Stewart 1,2,3,5 Departments of Global Health 1, Medicine 2, Epidemiology 3, Biostatistics 4, and Pediatrics 5, University of Washington, Seattle, WA, USA; Fred Hutchinson Cancer Research Center, Human Biology, Seattle, WA 6 ; Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya 7 No conflicts of interest to disclose Acknowledgements: Mama Salama Study participants and study staff, the Kenyan Ministry of Health, CDC/KEMRI, and the Ahero and Bondo District Hospitals Funding provided by NIH P01 HSD and CFAR P30 AI27757

Objective and population: Characterize virologic and immunologic responses among HIV-1 infected women with acute HIV-1 in pregnancy or postpartum initiating ART Study design and site: Prospective cohort study; Western Kenya Laboratory methods: Serial HIV-1 RNA nucleic acid amplification tests (NAATS); CD4 Statistical methods: Linear mixed effects models to measure changes in HIV-1 RNA Clinical and virologic characteristics post HIV-1 infection n n (%) or Median (IQR) Initiated ART At diagnosis (96) 21 (88) HIV-1 RNA levels at ART initiation (log 10 copies/mL) (4.22 – 5.68) Time to viral suppression (days)* (120, NA) CD4 count (cells/mm 3 ) At diagnosis 6 months post-diagnosis 6 month change (450 – 764) 831 (488 – 1066) 170 (21 – 375) HIV-1 incidence 1.9% (25/1304); incidence rate 2.35 per 100 PY 12 (48%) infections detected during pregnancy *< 2.17 log 10 copies/mL (150 copies/mL)

HIV-1 RNA levels post-ART initiation HIV-1 RNA levels by pregnancy status* Monthly rate of change** * Among 18 women with ≥2 plasma samples ** Infected during pregnancy vs. infected postpartum; p=0.06 Lower limit of detection HIV-1 RNA levels ~0.4 log 10 higher in acute infection compared to other chronically infected cohorts ART acceptable, resulted in rapid viral decline Prompt ART in acute infection important for PMTCT Long-term follow-up needed to assess durability of viral suppression Conclusions